{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+%2F+Metastatic+Solid+Tumors&page=6", "query": { "condition": "Locally Advanced / Metastatic Solid Tumors", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 432, "total_pages": 44, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+%2F+Metastatic+Solid+Tumors&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+%2F+Metastatic+Solid+Tumors&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T18:32:59.726Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02573259", "title": "A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Part 1", "MELANOMA", "SCCHN", "OVCA", "SARCOMA", "OTHER SOLID TUMORS", "Part 1 and 2", "NSCLC", "UROTHELIAL CARCINOMA" ], "interventions": [ { "name": "PF-06801591", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 147, "start_date": "2016-02-10", "completion_date": "2020-11-19", "has_results": true, "last_update_posted_date": "2021-12-13", "last_synced_at": "2026-10-07T18:32:59.726Z", "location_count": 24, "location_summary": "Los Angeles, California • Santa Monica, California • Louisville, Kentucky + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02573259" }, { "nct_id": "NCT03428802", "title": "Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "BRCA1 Gene Mutation", "BRCA2 Gene Mutation", "Locally Advanced Solid Neoplasm", "Metastatic Malignant Solid Neoplasm", "POLD1 Gene Mutation", "POLE Gene Mutation", "Recurrent Malignant Solid Neoplasm", "Recurrent Ovarian Carcinoma", "Stage III Breast Cancer AJCC v7", "Stage III Ovarian Cancer AJCC v8", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIA Ovarian Cancer AJCC v8", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIB Ovarian Cancer AJCC v8", "Stage IIIC Breast Cancer AJCC v7", "Stage IIIC Ovarian Cancer AJCC v8", "Stage IV Breast Cancer AJCC v6 and v7", "Stage IV Ovarian Cancer AJCC v8", "Stage IVA Ovarian Cancer AJCC v8", "Stage IVB Ovarian Cancer AJCC v8" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2018-03-08", "completion_date": "2027-09-21", "has_results": true, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-10-07T18:32:59.726Z", "location_count": 2, "location_summary": "New Brunswick, New Jersey • New York, New York", "locations": [ { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03428802" }, { "nct_id": "NCT06358677", "title": "Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Solid Tumor", "Locally Advanced Solid Tumor" ], "interventions": [ { "name": "Topical Tretinoin", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2025-02-19", "completion_date": "2029-07", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-10-07T18:32:59.726Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT06358677" }, { "nct_id": "NCT06258304", "title": "A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic Solid Tumor Malignancies" ], "interventions": [ { "name": "GIGA-564", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GigaGen, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2024-05-08", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2025-04-10", "last_synced_at": "2026-10-07T18:32:59.726Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06258304" }, { "nct_id": "NCT02517398", "title": "MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "MSB0011359C", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 600, "start_date": "2015-08-31", "completion_date": "2022-05-23", "has_results": true, "last_update_posted_date": "2024-05-03", "last_synced_at": "2026-10-07T18:32:59.726Z", "location_count": 36, "location_summary": "Tucson, Arizona • Escondido, California • Sacramento, California + 32 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Escondido", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Whittier", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02517398" }, { "nct_id": "NCT07038343", "title": "AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor Cancer", "Locally Advanced", "Metastatic Solid Tumors", "Lung Cancers", "Epithelial Tumor", "Biliary Tract Cancer (BTC)", "Urothelial Cancer", "Nasopharyngeal Cancers" ], "interventions": [ { "name": "AVZO-1418", "type": "DRUG" }, { "name": "Combination Agent 1", "type": "DRUG" }, { "name": "Combination Agent 2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avenzo Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 480, "start_date": "2025-06-04", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-10-07T18:32:59.726Z", "location_count": 19, "location_summary": "Gilbert, Arizona • Los Angeles, California • Denver, Colorado + 15 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT07038343" }, { "nct_id": "NCT06625515", "title": "First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Breast Cancer Recurrent", "Colorectal Cancer Metastatic", "Colon Cancer", "Rectal Adenocarcinoma", "Endometrial Cancer" ], "interventions": [ { "name": "ATX-559", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Accent Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2024-10-11", "completion_date": "2026-01-09", "has_results": false, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-10-07T18:32:59.726Z", "location_count": 5, "location_summary": "Aurora, Colorado • Oklahoma City, Oklahoma • Nashville, Tennessee + 2 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06625515" }, { "nct_id": "NCT06364410", "title": "Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Locally Advanced Gastric Carcinoma", "Locally Advanced Gastroesophageal Junction Adenocarcinoma", "Locally Advanced Malignant Solid Neoplasm", "Metastatic Gastric Carcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Metastatic Malignant Solid Neoplasm", "Unresectable Gastric Carcinoma", "Unresectable Gastroesophageal Junction Adenocarcinoma", "Unresectable Malignant Solid Neoplasm" ], "interventions": [ { "name": "Azenosertib", "type": "DRUG" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Trastuzumab Deruxtecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2025-02-03", "completion_date": "2027-07-08", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-10-07T18:32:59.726Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06364410" }, { "nct_id": "NCT04969835", "title": "A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Salivary Gland Tumor", "Urothelial Carcinoma", "Ovarian Carcinoma", "Breast Cancer", "Soft Tissue Sarcoma" ], "interventions": [ { "name": "AVA6000", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avacta Life Sciences Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 158, "start_date": "2021-07-16", "completion_date": "2027-08-06", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-07T18:32:59.726Z", "location_count": 3, "location_summary": "New York, New York • Houston, Texas • Seattle, Washington", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04969835" }, { "nct_id": "NCT07213817", "title": "A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced Solid Tumor", "Metastatic Solid Tumor" ], "interventions": [ { "name": "IPN60300", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Ipsen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 114, "start_date": "2025-12-05", "completion_date": "2028-10-30", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-07T18:32:59.726Z", "location_count": 6, "location_summary": "New Haven, Connecticut • Grand Rapids, Michigan • Philadelphia, Pennsylvania + 3 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07213817" } ] }